Multivalent Communications

Based in Boston, Massachusetts, Multivalent Communications (MVC) operates at the intersection of science, strategy, and storytelling. Boston is home to one of the most concentrated clusters of biotechnology, pharmaceutical, and academic medical research in the United States, creating a natural market for a firm that specializes in translating complex technical information into clear, audience-appropriate communications. Founded in 2024, Multivalent Communications was established to serve the Life Sciences and Chemicals sectors, drawing its name from the concept of multivalent materials that engage multiple receptors simultaneously—a fitting metaphor for a communications agency that aims to reach diverse stakeholders through unified messaging.

What They Do

Multivalent Communications focuses on synthesizing and sharing technical information across a spectrum of audiences, from expert researchers and clinicians to the general public and investors. The agency’s core offering spans strategic consulting, scientific and medical writing, content development, and research services. Rather than positioning themselves as a generalist PR firm, Multivalent Communications deliberately concentrates on the nuances of scientific and medical communications, where accuracy, credibility, and regulatory awareness are paramount. Their work often involves literature research, data analysis, and data visualization to support publication planning, slide deck development, and other materials that require rigorous evidence-based messaging. The firm also provides editing, storyboarding, and pitch development refinement, helping clients shape narratives that are both scientifically sound and strategically targeted.

Who They Serve

Multivalent Communications serves organizations within the pharmaceuticals, biotech, and chemicals industries. These clients typically need to communicate with multiple stakeholder groups simultaneously, including regulatory bodies, healthcare professionals, investors, and the general public. The agency’s services are designed to bridge the gap between expert-level technical writing and broader public relations efforts. For example, they offer expert-to-expert communication and technical writing for scientific audiences, while also providing public and media relations, social media management, and public education campaigns for lay audiences. This dual capability makes Multivalent Communications a practical partner for companies launching new therapies, managing clinical trial communications, or navigating complex regulatory landscapes. The agency also offers communications coaching and training, which can be particularly valuable for internal teams needing to refine their own messaging skills.

Areas of Expertise

Multivalent Communications brings together a range of specialized skills that are particularly relevant for science-driven organizations. Their likely services include:

• Scientific and medical writing, including ghostwriting and editing
• Publication planning and slide deck development
• Content strategy and development for digital and print channels
• Literature research and data analysis for evidence-based communications
• Data visualization to make complex information accessible
• Public and media relations, including pitch development and refinement
• Social media strategy and audience engagement
• Stakeholder and investor relations communications
• Communications coaching and training for internal teams

These capabilities reflect a firm that understands the technical depth required in life sciences communications while also recognizing the importance of clear, compelling narratives for non-specialist audiences. Multivalent Communications’ approach is grounded in research and strategy, ensuring that content is not only accurate but also aligned with broader business and communication goals.

Who Multivalent Communications Is a Good Fit For

Multivalent Communications is best suited for organizations in the life sciences and chemicals sectors that need a partner capable of handling both highly technical writing and broader public communications. Early-stage biotech companies preparing for investor presentations, established pharmaceutical firms managing product launches, and chemical companies navigating public education or stakeholder engagement would all find value in the agency’s focused expertise. Because Multivalent Communications is a relatively new firm, founded in 2024, clients may benefit from a more agile, hands-on approach compared to larger, more established agencies. For those seeking a Boston-based partner that understands the specific communications challenges of science-driven industries, Multivalent Communications offers a targeted and practical solution.